Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Aura Biosciences, Inc. (AURA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/09/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Strengthened Clinical and Regulatory Leadership Team with Key Appointments Start-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023 BOSTON, MA – August 9, 2023 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights. “As we build momentum across our portfolio, we are happy to welcome Drs. Bruce Brown and A...",
"OTHER SOLID TUMORS OCULAR ONCOLOGY"
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal Melanoma Enrollment Complete in Phase 2 Trial in Choroidal Melanoma Using Suprachoroidal Route of Administration BOSTON, MA – May 11, 2023 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2023, and provided clinical development and operational highlights. “We are encouraged by our recent interactions with the FDA in support of our global Phase 3 trial designed to en...",
"OTHER SOLID TUMORS OCULAR ONCOLOGY"
04/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/15/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration Grants Fast Track Designation for Belzupacap Sarotalocan for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON, MA – March 15, 2023 – Aura Biosciences, Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights. “2023 is off to a..."
01/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate presentation of the Company",
"Corporate presentation of the Company"
12/05/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between the Company, SVB Securities, Cowen and Evercore ISI, as representatives of the several underwriters named therein",
"Opinion of Goodwin Procter LLP"
11/30/2022 8-K Quarterly results
10/03/2022 8-K Quarterly results
09/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aura Biosciences Announces First Patient Dosed in Phase 1study Evaluating Belzupacap Sarotalocan for the Treatment of Non-Muscle Invasive Bladder Cancer BOSTON, MA - September 28, 2022 - Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1study evaluating belzupacap sarotalocan, the Company's first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer . “Dosing of the first patient in this Phase 1study is an exciting key milestone both for Aura and for the field of urologic oncology, as approximately 70% of patients with bladder cancer globally are diagnosed early with NMIBC,” said Dr. Cadmus Rich..."
08/11/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
Docs: "Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022 Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma John Maraganore, Ph.D., Joins as a Strategic Advisor CAMBRIDGE, MA – March 23, 2022 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided clinical development and operational highlights. “We have begun 202..."
11/24/2021 8-K Quarterly results
Docs: "Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Presented Final Data from Phase 1b/2 Trial of AU-011 in Choroidal Melanoma at the American Academy of Ophthalmology’s Annual Meeting Completed Initial Public Offering to Fund Pivotal Program for AU-011 in Choroidal Melanoma and Earlier Stage Oncology Pipeline CAMBRIDGE, MA – November 24, 2021 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications including ocular and urologic cancers, today announced financial results for the third quarter ended September 30, 2021. “We recently completed a successful initial public offering, placing us in a solid financial..."
11/02/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy